Scientists from the National Institute for Biological Standards and Control (NIBSC) played a leading role in the development of a the novel oral polio vaccine type 2 (nOPV2) as an essential new tool in the fight against vaccine-derived poliovirus type 2 (cVDPV2).  This month, the Strategic Advisory Group of Experts on Immunization (SAGE) – an independent group of scientific experts that advises the World Health Organization (WHO) on vaccines and immunization – has endorsed the strong safety performance of nOPV2 use in real-world settings. 

Read more